Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs Stryker Corporation (SYK) Price & Performance

Davita IncTrade
Stryker CorporationTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs Stryker Corporation — how do they compare? Davita Inc trades at $179.02 (market cap $11.72B), while Stryker Corporation trades at $346.62 (market cap $132.64B). The key difference: Stryker Corporation is far larger — about 11.3× Davita Inc's market cap, and Stryker Corporation pays a 1.02% dividend while Davita Inc pays none. Which is the better fit depends on your goals.

DVASYK
Market Cap
$11.72B$132.64B
Sector
HealthTechnology
52-Week High
$240.96$394.34
52-Week Low
$103.87$282.58
Enterprise Value
$24.44B$144.11B
Dividend Yield
1.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.

The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.

Stryker Corporation

Stryker (SYK) trades at $339.03, up 0.47% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $3.69 versus $3.49 expected, and demonstrated robust 9% organic sales growth. Analyst consensus is strongly positive with a $379.44 price target and 74% buy ratings. Recent news highlights recovery from a cybersecurity incident and the launch of Mako RPS robotic technology.

The outlook remains favorable given earnings momentum and product innovation, though risks include competitive pressures and potential cyber disruptions. Valuation multiples such as a P/E of 35.84 suggest premium pricing, requiring sustained growth to justify. Institutional ownership trends show mixed activity, with some funds increasing stakes recently.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK